Provided by Tiger Trade Technology Pte. Ltd.

Atrium Therapeutics

14.75
-0.0310-0.21%
Post-market: 14.23-0.5512-3.73%17:46 EST
Volume:7.93M
Turnover:123.09M
Market Cap:2.28B
PE:- -
High:15.93
Open:14.58
Low:13.06
Close:14.78
52wk High:73.06
52wk Low:13.06
Shares:154.74M
Float Shares:132.00M
Volume Ratio:1.25
T/O Rate:6.01%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-4.9715
ROE:-43.98%
ROA:-26.47%
PB:1.35
PE(LYR):-2.97

Loading ...

Avidity Biosciences Inc : RBC Cuts to Sector Perform From Outperform; Raises Target Price to $72 From $61

THOMSON REUTERS
·
Oct 28, 2025

Avidity Biosciences (RNA) was downgraded to a Hold Rating at Chardan Capital

TIPRANKS
·
Oct 28, 2025

This biotech's stock soared as investors look for the next buyout target

Dow Jones
·
Oct 28, 2025

Quest Laboratories Advances RNA Vaccine Study for Crimean-Congo Hemorrhagic Fever

TIPRANKS
·
Oct 28, 2025

Top Midday Gainers

MT Newswires Live
·
Oct 28, 2025

Dyne Therapeutics Shares Rise After Novartis Reaches Deal to Buy Avidity

Dow Jones
·
Oct 28, 2025

BUZZ-U.S. STOCKS ON THE MOVE-PepGen, Turbo Energy, Qualcomm

Reuters
·
Oct 28, 2025

BUZZ-PepGen, Dyne rise after Novartis' $12 bln deal to buy rival Avidity

Reuters
·
Oct 27, 2025

Novartis' Avidity Deal Is a Green Light for Biotech Rally -- Barrons.com

Dow Jones
·
Oct 27, 2025

Avidity Biosciences downgraded to Neutral from Buy at Citi

TIPRANKS
·
Oct 27, 2025

Avidity Biosciences downgraded to Market Perform from Outperform at Leerink

TIPRANKS
·
Oct 27, 2025

Avidity Biosciences Inc : Leerink Partners Cuts to Market Perform From Outperform; Raises Target Price to $72 From $65

THOMSON REUTERS
·
Oct 27, 2025

Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday

Benzinga
·
Oct 27, 2025

Avidity Biosciences Up Over 42%, on Track for Record High Close -- Data Talk

Dow Jones
·
Oct 27, 2025

Avidity Biosciences rises 42.8%

TIPRANKS
·
Oct 27, 2025

Avidity Biosciences Shares up About 43% After Novartis to Acquire Co for About $12 Bln

THOMSON REUTERS
·
Oct 27, 2025

Sector Update: Health Care Stocks Mixed Premarket Monday

MT Newswires Live
·
Oct 27, 2025

Novartis CEO Says Co Plans to Discuss Potential for Accelerated Approval With US FDA for Avidity's Fshd Therapy

THOMSON REUTERS
·
Oct 27, 2025

Novartis CEO, on Avidity Deal, Says "It's an Appropriate Risk to Take"

THOMSON REUTERS
·
Oct 27, 2025

Novartis CFO Says Avidity Deal in Line With Co's Strategy of Bolt-on Acquisitions- Conf Call

THOMSON REUTERS
·
Oct 27, 2025